Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma (NCT06947083)

🔬

Loading study...

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma (NCT06947083) | TrialReferrals